Pharmacokinetics: Factors Affecting Drug Absorption and pH Partitioning Theory

Bioavailability represents the proportion of an administered dose that becomes available at the site of pharmacological action. For intravenous administration, bioavailability is 100% by definition; for other routes, bioavailability is calculated as the ratio of the area under the plasma concentration–time curve (AUC) to the dose administered, typically expressed as AUC ÷ Dose.

The pH partitioning theory, also known as the ion-trapping hypothesis, explains how the ionization state of a drug influences its permeability across biological membranes. According to this theory, weak acids and bases exist in equilibrium between ionized and non‑ionized forms, with the non‑ionized species exhibiting greater lipophilicity and membrane permeability. The distribution of these species is governed by the Henderson–Hasselbalch equation:

pH = pK_a + log([A^–]/[HA]) for weak acids, and pH = pK_a + log([B]/[BH⁺]) for weak bases.

Membrane partition coefficients (K) quantify the relative solubility of a drug in lipid versus aqueous phases and are pivotal in predicting absorption across lipid membranes.

Theoretical Foundations

Transport across biological membranes can be described by passive diffusion, facilitated diffusion, and active transport mechanisms. Passive diffusion follows Fick’s first law, whereby the flux (J) is proportional to the concentration gradient and the membrane permeability coefficient (P): J = P × ΔC. The permeability coefficient itself is a function of the drug’s lipophilicity, molecular size, and ionization state.

In the intestinal epithelium, the luminal pH varies from approximately 1.2 in the stomach to 7.4 in the terminal ileum, creating a gradient that influences the ionization of orally administered drugs. The pH partitioning theory predicts that a weak base will be predominantly ionized in acidic stomach fluid, reducing permeability, but will become non‑ionized in the more neutral intestinal fluid, thereby enhancing absorption. Conversely, a weak acid will be non‑ionized in the stomach and become ionized in the intestine, leading to decreased permeability downstream.

Mathematical models such as the zero‑order, first‑order, and transit compartment models are employed to characterize absorption kinetics. For instance, a first‑order absorption model yields the concentration–time relationship: C(t) = (F × Dose × k_a)/(V_d (k_a – k_el)) × (e^-k_elt – e^-k_at), where V_d is the apparent volume of distribution and k_el is the elimination rate constant.

Key Terminology

• Fraction absorbed (F): proportion of the dose that reaches systemic circulation.
• Permeability coefficient (P): measure of membrane permeability to a drug.
• Partition coefficient (K): ratio of concentrations of a drug in two immiscible phases (e.g., octanol/water).
• First‑order absorption (k_a): rate constant describing exponential uptake into circulation.
• Bioavailability (F_bio): relative extent of systemic exposure after non‑IV administration.
• pK_a: pH at which a drug is 50% ionized.
• Transit compartments: conceptual stages representing sequential absorption sites.

Detailed Explanation

Mechanisms of Absorption

Drug absorption into systemic circulation can occur via multiple pathways:

• Passive diffusion: driven by concentration gradients across lipid bilayers; most common for lipophilic, non‑ionized molecules.
• Facilitated diffusion: mediated by carrier proteins; important for substrates like glucose and amino acids.
• Active transport: energy‑dependent uptake; exemplified by P-glycoprotein efflux and organic anion transporting polypeptides (OATPs).
• Paracellular transport: passage through tight junctions; typically limited to small, hydrophilic molecules.

The relative contribution of each mechanism depends on drug properties, formulation characteristics, and physiological conditions.

Physicochemical Determinants

Several intrinsic physicochemical attributes modulate absorption:

• Ionization state: Non‑ionized forms exhibit higher lipophilicity and membrane permeability; ionized species are less permeable and may be subject to efflux transporters.
• pK_a and pH: The Henderson–Hasselbalch equation predicts the proportion of ionized versus non‑ionized drug across the gastrointestinal tract. For weak bases, optimal absorption often occurs in the small intestine where pH is higher; for weak acids, absorption is favored in the acidic stomach.
• Molecular weight: Molecules < 500 Da typically permeate epithelial membranes more readily; larger molecules may require carrier-mediated transport.
• LogP (octanol/water partition coefficient): Reflects lipophilicity; values between 1 and 3 are generally favorable for passive absorption.
• Solubility: Poorly soluble drugs may form supersaturated solutions or require formulation strategies such as nanoparticles or micronization to enhance dissolution.
• Stability: Chemical or enzymatic degradation in the gastrointestinal lumen can reduce the amount of intact drug available for absorption.

Biological Determinants

Host factors influence drug absorption through alterations in gastrointestinal physiology and transporter expression:

• Gastrointestinal pH: Gastric acid secretion varies with age, diet, and disease; hypoacidic states (e.g., atrophic gastritis) can impair absorption of weakly acidic drugs.
• Motility: Gastric emptying and intestinal transit times affect the duration a drug remains in contact with absorptive surfaces.
• Enzyme activity: First‑pass metabolism by intestinal cytochrome P450 enzymes (particularly CYP3A4) can reduce bioavailability.
• Transporter expression: Polymorphisms or drug‑induced changes in efflux (e.g., P-gp) and uptake (e.g., OATP) transporters alter absorption rates.
• Microbiome: Gut flora can metabolize certain drugs, generating metabolites that may or may not be absorbed.

Formulation Factors

Drug delivery systems are engineered to modulate absorption characteristics:

• Immediate‑release tablets: Designed for rapid dissolution; absorption is limited by dissolution rate and dissolution surface area.
• Controlled‑release formulations: Aim to sustain drug release over extended periods, often by encapsulation in hydrophilic polymers or coating with rate‑limiting materials.
• Transdermal patches: Rely on passive diffusion across skin layers; permeation enhancers such as ethanol or oleic acid increase stratum corneum fluidity.
• Nanoparticles and liposomes: Increase surface area, improve solubility, and may facilitate uptake via endocytosis.
• Salt forms: Salts with different anions can modify solubility profiles, thereby affecting dissolution and absorption.

pH Partitioning Theory

The pH partitioning theory posits that the ionization state of a drug determines its ability to cross lipid membranes. According to the theory, the concentration of the non‑ionized species (C_non‑ion) at a given pH is described by:

C_non‑ion = C_total ÷ (1 + 10^{pH – pK_a}) for weak acids, and C_non‑ion = C_total ÷ (1 + 10^{pK_a – pH}) for weak bases.

Because only the non‑ionized fraction permeates membranes, a drug’s absorption can be predicted by integrating the non‑ionized fraction over the pH range of the absorption site. For example, a weak base with pK_a 8.5 will be largely ionized at gastric pH 1.2, limiting absorption in the stomach; however, as it traverses into the ileum where pH approaches 7.4, the non‑ionized proportion rises, facilitating absorption. Conversely, a weak acid with pK_a 4.5 will be largely non‑ionized in the stomach, enabling rapid uptake, but will become ionized in the intestine, leading to reduced permeability.

Mathematical modeling of pH partitioning involves integrating the permeability over the gastrointestinal tract’s length, accounting for transit time and pH gradient. Such models can predict the fraction absorbed (F) as a function of drug properties and physiological parameters, and are valuable in early drug development for screening absorption potential.

Mathematical Relationships and Models

Several quantitative frameworks are employed to describe absorption kinetics:

• Zero‑order absorption: C(t) = (F × Dose ÷ t_lag) × (1 – e^-k_elt), applicable to formulations with a constant release rate.
• First‑order absorption (standard model): C(t) = (F × Dose × k_a)/(V_d (k_a – k_el)) × (e^-k_elt – e^-k_at).
• Transit compartment model: A series of compartments (n) with identical transit times (τ) leading to a lag time of n × τ; useful for simulating delayed absorption.
• Bioavailability calculation: F = (AUC_non‑IV ÷ AUC_IV) × (Dose_IV ÷ Dose_non‑IV).

These equations enable estimation of key pharmacokinetic parameters such as C_max, t_max, and t_1/2 based on observed concentration–time data.

Factors Affecting the Process

Absorption variability arises from a complex interplay of factors:

• Food effects: High-fat meals can increase solubility of lipophilic drugs but may delay gastric emptying.
• Drug–drug interactions: Concomitant inhibitors of efflux transporters can enhance absorption; inducers of metabolizing enzymes may reduce bioavailability.
• Genetic polymorphisms: Variants in transporter genes (e.g., ABCB1, SLCO1B1) can alter absorption rates.
• Age and disease states: Neonates possess immature intestinal barriers, while elderly patients may exhibit reduced gastric acid secretion.
• Formulation modifications: Controlled‑release devices may reduce peak concentrations, affecting both efficacy and safety profiles.

Clinical Significance

Relevance to Drug Therapy

Understanding absorption determinants informs therapeutic drug monitoring, dosage adjustment, and the selection of appropriate drug delivery systems. For instance, drugs with high first‑pass metabolism may benefit from alternative routes such as sublingual or transdermal administration to bypass hepatic extraction. Conversely, drugs that are pH‑sensitive may require enteric coating to protect them from gastric degradation.

Clinicians must consider patient-specific factors that affect absorption, such as gastrointestinal motility disorders, concurrent medications that alter pH or transporter activity, and genetic polymorphisms affecting drug disposition. Failure to account for these variables can lead to subtherapeutic concentrations, therapeutic failure, or adverse drug reactions.

Practical Applications

In clinical practice, absorption knowledge is applied in several scenarios:

• Formulation selection: Choosing between immediate‑release versus delayed‑release tablets based on the drug’s absorption window.
• Dose optimization: Adjusting dosing intervals to maintain plasma concentrations within the therapeutic window when absorption is variable.
• Drug interaction management: Monitoring for interactions that affect gastric pH (e.g., proton pump inhibitors) or transporter activity.
• Patient counseling: Advising patients on food interactions, timing of doses relative to meals, and adherence to specific administration guidelines.

Clinical Examples

Several drugs illustrate the importance of absorption principles:

• Omeprazole: A weak base that is protonated in the acidic stomach, limiting absorption; however, a delayed‑release formulation releases the drug in the intestine where pH is higher, enhancing uptake.
• Amoxicillin: A weak acid with high solubility in acidic media; its absorption is maximal in the stomach and decreases in the small intestine.
• Furosemide: A weak base with high lipophilicity; its absorption is significantly reduced when taken with high‑fat meals due to delayed gastric emptying.
• Fentanyl transdermal patch: Relies on passive diffusion across skin; permeation enhancers are incorporated to increase skin fluidity and drug flux.

Clinical Applications/Examples

Case Scenario 1: Variable Absorption in a Patient with Gastric Ulcer Disease

A 65‑year‑old woman with chronic gastritis presents for evaluation of inadequate therapeutic response to an oral weak base antihypertensive. Gastric pH is elevated due to atrophic gastritis, reducing the ionization of the drug in the stomach and thereby limiting absorption. Switching to a transdermal formulation or a formulation that releases the drug in the small intestine could improve bioavailability.

Case Scenario 2: Food Interaction Affecting Lipophilic Drug

A 45‑year‑old man taking a high‑lipophilicity statin reports intermittent muscle pain. The statin’s absorption is markedly increased when taken with a high‑fat meal, leading to supratherapeutic plasma concentrations and myopathy. Counseling to take the medication on an empty stomach can mitigate this interaction.

Case Scenario 3: Drug–Drug Interaction with P‑glycoprotein Inhibition

A patient on a weak base antidepressant concurrently initiates therapy with a potent P‑glycoprotein inhibitor. Inhibition of the efflux transporter increases the drug’s absorption, potentially precipitating serotonin syndrome. Dose reduction or alternative medication selection may be warranted.

Problem‑Solving Approach

When confronted with unexpected absorption variability, a systematic evaluation should include:

• Assessment of drug physicochemical properties (pK_a, logP, solubility).
• Examination of patient factors (age, gastrointestinal pH, motility, comorbidities).
• Review of concomitant medications that alter pH or transporter activity.
• Consideration of formulation changes (e.g., enteric coating, controlled‑release design).
• Utilization of pharmacokinetic modeling to predict absorption profiles and guide therapeutic adjustments.

Summary/Key Points

• Drug absorption is governed by physicochemical attributes (ionization state, pK_a, logP, molecular weight), biological factors (pH, motility, enzyme and transporter activity), and formulation characteristics.
• The pH partitioning theory explains how the ionization state influences membrane permeability, with non‑ionized species exhibiting superior absorption across lipid membranes.
• Mathematical models—including first‑order and transit compartment frameworks—provide quantitative predictions of absorption kinetics and enable estimation of key pharmacokinetic parameters.
• Clinical implications encompass drug selection, dosing strategy, formulation choice, and management of drug–drug interactions that alter absorption.
• Patient‑specific variables such as age, disease state, and genetic polymorphisms must be considered to tailor therapy and achieve optimal therapeutic outcomes.

References

1. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. 7th ed. New York: McGraw-Hill Education; 2016.
2. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Philadelphia: Wolters Kluwer; 2011.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.